Clinical Trial

ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC

Study acronym: PRESERVE-006
Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
In this Phase 2 study, mCRPC patients with PSMA positive scans who progressed on prior ARTA and up to 2 lines of taxanes, and are naïve to lutetium Lu 177 vipivotide tetraxetan, will be enrolled. The study is open-label, randomized with active control, multi-center study.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-06-30 -> 2026-11-30 2026-05-23
minor Completion pushed: 2027-06-30 -> 2027-11-30 2026-05-23
Trial Details
NCT Number NCT05682443
Lead Sponsor OncoC4, Inc.
Collaborators: Prostate Cancer Clinical Trials Consortium
Conditions Metastatic Castration-resistant Prostate Cancer
Enrollment 148 participants
Start Date 2023-12-11
Primary Completion 2026-11-30 (estimated)
Study Completion 2027-11-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-22